Sara A. Hurvitz, MD


Selecting Novel Adjuvant Therapy For Patients With Breast Cancer

May 25th 2022

Following their discussion on the OlympiA and monarchE trials in breast cancer, experts consider when they would use olaparib or abemaciclib in the adjuvant setting.

Adjuvant Abemaciclib in Early Breast Cancer: The monarchE Trial

May 25th 2022

Shared insight on the monarchE trial, which studied adjuvant abemaciclib in patients with HR+, HER2- high-risk early breast cancer.

Impact of Molecular Testing on Treatment Options in Breast Cancer

May 11th 2022

Shared insight on specific treatment options in breast cancer made available when patients are found to have actionable targets via molecular testing.

Molecular Testing Platforms in Breast Cancer

May 11th 2022

Expert perspectives on platforms for molecular testing in breast cancer, as well as the actionable targets that treating physicians should be looking for.

SABCS 2021 Updates in Key Clinical Trials for Breast Cancer

February 14th 2022

Patrick Neven MD, PhD; Sara A. Hurvitz, MD; Kevin Kalinsky, MD, MS; and Aditya Bardia, MD, MPH, share insight on updates in key clinical trials and novel therapies in breast cancer presented at SABCS 2021.

SABCS 2021 Updates in CDK4/6 Inhibitors in Breast Cancer

February 7th 2022

Sara A. Hurvitz, MD; Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky MD, MS, discuss SABCS 2021 updates on the use of CDK4/6 inhibitors in HR+/HER2 breast cancer.

SABCS 2021 Updates in ER+ Breast Cancer

January 31st 2022

Experts in the management of breast cancer review recent data on SERDs (selective estrogen receptor degraders) in ER+/HER2 advanced breast cancer presented at SABCS [San Antonio Breast Cancer Symposium] 2021.

Dr. Hurvitz on the Key Objectives of DESTINY-Breast03 in HER2+ Breast Cancer

December 21st 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 3 DESTINY-Breast03 trial examining in HER2-positive breast cancer.

Advances Treating HR+ Metastatic Breast Cancer

December 6th 2021

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.

Novel Therapies Under Investigation for HR+ MBC

December 6th 2021

An overview of key presentations from ESMO 2021 that continues studying the potential effect of novel-based treatment options for use in hormone receptor-positive metastatic breast cancer.

PI3K Inhibitors for HR+ MBC

November 29th 2021

The relevance of PIK3CA mutations in terms of the pathophysiology of HR-positive metastatic breast cancer, and lessons learned in practice and via clinical studies in terms of sequencing therapy with PI3K inhibitors.

HR+ MBC: Palbociclib Plus Endocrine Therapy on Time to Chemotherapy

November 22nd 2021

The rationale for conducting a post-hoc analysis of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive metastatic breast cancer as presented at ESMO 2021.

HR+ MBC: Abemaciclib Plus Endocrine Therapy

November 22nd 2021

Clinical implications of a pooled analysis of endocrine therapy-naïve participants in MONARCH 2 investigating the use of abemaciclib plus fulvestrant to treat hormone receptor-positive metastatic breast cancer.

ESMO 2021: Updates in Triple Negative Breast Cancer

November 15th 2021

Drs Joyce O’Shaughnessy, Sara Tolaney, Sara Hurvitz, and Mark Pegram examine recent trial data from ESMO 2021 on triple-negative breast cancer.

First-Line Approaches for HR+ Metastatic Breast Cancer

November 10th 2021

Options available as first-line therapy for HR+ metastatic breast cancer and variables that impact which CDK4/6 inhibitor and endocrine partner is selected for a patient.

Updates in HR+/HER2- Breast Cancer: The MONALEESA-2 Trial

November 8th 2021

Breast oncologists explain results from the phase III MONALEESA-2 trial presented at ESMO 2021, and its clinical implications.

Interesting Trials in HER2+ Breast Cancer

November 1st 2021

Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.

Updates in HER2+ Breast Cancer from ESMO 2021

October 25th 2021

Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.

Dr. Hurvitz on the Rationale for the coopERA Breast Cancer Trial in ER+/HER2- Breast Cancer

September 29th 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Hurvitz on Outcomes With Sacituzumab Govitecan in TNBC

September 1st 2021

Sara A. Hurvitz, MD, discusses outcomes with sacituzumab govitecan-hziy in patients with metastatic triple-negative breast cancer.